Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Intelligent Chemical Design | Main | The Voice of Experience »

May 24, 2005

You Figure It Out

Email This Entry

Posted by Derek

This is as much an economics post as a pharmaceutical one. I noticed this headline from AllAfrica.com, from a newspaper in Lusaka, Zambia: "Imported Pharmaceutical Products Hindering Growth." Curious, I read the whole piece, and I have to say that it makes my head hurt. Here, you judge: Says the head of Pharmanova Zambia, one of the country's only pharmceutical manufacturers,

"The government must reduce on imported products such as drugs. For example, if you import drugs from India, you are giving the Indian government access to growth of their economy and that does not benefit the Zambian economy at all," Dharkar said.

"What we want as manufacturers of pharmaceutical products is support from our government. We are capable of producing high quality drugs for the Zambian community."

Now, break that statement down. What Mr. Dharkar wants is "support" from his government - by which I assume he means high tariffs - so he can make all the money from the Zambian pharmaceutical market himself. This, as far as I can see, benefits his customers not one tiny bit, and it only benefits his employees until they need to buy some drugs themselves. And it's supposed to benefit the Zambian economy. . .how, exactly?

Look, this is not an intellectual property issue, and it's not an issue of recouping research costs (as it is in the US market.) We're not going to get our costs back from Zambia, a desperately poor country full of desperately poor people. As far as I can see, protecting this local factory will only cause these people to pay more for their medicines. And Mr. Dharkar agrees, but then he disagrees, right in the same paragraph:

Dharkar said most Zambian communities needed locally produced drugs, which he said would be more affordable than the imported drugs. He said his company was capable of producing antiretroviral drugs, although he observed that the high cost of producing the drugs would hinder their production in Zambia.

Now, if his drugs are more affordable, why isn't he wiping the imported stuff right out of the market by undercutting them? What's stopping him? And as for those antiretrovirals, which Zambia most definitely needs, if the cost of producing them locally is too high, then why not. . .import them from India? Aaargh.

Comments (2) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. jeet on May 25, 2005 12:44 PM writes...

Looks like a pretty straightforward request for import quota to help protect/ expand the pharma industry within the country.



There are a lot of reasons why you wouldn't want to do this with therapeutics, especially for compounds not already made within the country, but this is pretty similar to import tariffs for steel (US), textiles (US), foodstuff (Japan), etc. that are used in most countries. Or, other tactics like export tarrifs (China), byzantine regulations (Japan), subsidies (US), voluntary export restrictions (Japan) can be used for the same net effect, that is giving domestic industry a leg up on the competition.

Permalink to Comment

2. Derek Lowe on May 25, 2005 1:20 PM writes...

Jeet, you're absolutely right about those comparisons, and I find all of them equally odious. What's done in the US with the likes of sugar, steel, and textiles is outrageous.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .